Multifunctional small-molecule theranostic agents hold significant clinical potential for non-invasive endometriosis (EMS) management. Current EMS treatment faces challenges due to imprecise lesion localization and therapy-associated side effects. Herein, an integrated …
Endometriosis (EMs) is a common inflammatory disorder in women of reproductive age, severely impacting patients' quality of life and fertility. Current hormonal therapies offer limited efficacy, and surgical interventions often …
Endometriosis is hypothesized to result from retrograde menstruation where cell debris including endometrial stromal cells (ESCs) travel through the fallopian tubes. This chronic inflammatory disease is characterized by inflammatory and …
Medical therapy is crucial in the long-term management of endometriosis, and its clinical efficacy must be balanced with a favorable safety profile.
Adenomyosis and endometriosis, two common estrogen-dependent benign gynecological disorders usually present with overlapping symptoms, such as pain and infertility. These two conditions often co-exist and are associated with poor reproductive …
The human endometrium is a dynamic tissue that lines the uterus and undergoes constant remodeling, making it especially susceptible to gynecological diseases like endometriosis and endometrial cancer. The molecular mechanisms …
As a common chronic disease, endometriosis (EMs) affects nearly 10% of women of childbearing age, may cause other complications such as infertility, and has a tendency to develop malignant tumors. …
Immune-related factors may serve an important role in the development of endometriosis, considering the occurrence of substantial abnormalities in the immune system of women with endometriosis, including reduced T-cell reactivity …
Limited research has examined psychological treatments for endometriosis-related chronic pain, despite its association with elevated disability, depression, and anxiety. Remotely delivered treatments have the potential to overcome barriers to access …
The objective of this study was to compare the quality of life in patients with endometriosis undergoing treatment with progestins, OCPs, and GnRH agonists.